Monitoring Minimal Residual Disease in RUNX1 -Mutated Acute Myeloid Leukemia

Boaz Nachmias; Svetlana Krichevsky; Dvora Filon; Ehud Even-Or; Moshe E. Gatt; Revital Saban; Batia Avni; Sigal Grisariu; Shlomzion Aumann; Vladimir Vainstein

doi:10.1159/000526353

Monitoring Minimal Residual Disease in RUNX1 -Mutated Acute Myeloid Leukemia

Boaz Nachmias^*
, Svetlana Krichevsky
, Dvora Filon
, Ehud Even-Or
, Moshe E. Gatt
, Revital Saban
, Batia Avni
, Sigal Grisariu
, Shlomzion Aumann
, Vladimir Vainstein

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Introduction: Mutated RUNX1 is considered a poor prognostic factor and usually is mutually exclusive with NPM1 mutations. Monitoring of molecular markers for minimal residual disease provides a powerful tool to assess remission and guide clinical decisions. Methods: Newly diagnosed RUNX1-mutated AML patients, designated to intensive chemotherapy-based treatment or nonintensive regimens, were monitored for mutated RUNX1 transcript levels by qPCR with patient-specific primers. Samples were obtained along the treatment course and follow-up. Results: A clear correlation was observed between mutated RUNX1 levels and response to treatment as observed by flow cytometry and STR-based assessment. Conclusion: We demonstrate the feasibility of RUNX1-based MRD to correlate with the clinicopathological status of leukemia. We further suggest how RUNX1 qPCR monitoring can influence clinical decision-making and contribute to improved personalized patient care.

Original language	English
Pages (from-to)	642-649
Number of pages	8
Journal	Acta Haematologica
Volume	145
Issue number	6
DOIs	https://doi.org/10.1159/000526353
State	Published - 1 Nov 2022

Bibliographical note

Publisher Copyright:
© 2022 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Acute myeloid leukemia
Minimal residual disease
RUNX1 mutation

Access to Document

10.1159/000526353

Cite this

@article{c6177925516b48b79e243391023a8b15,

title = "Monitoring Minimal Residual Disease in RUNX1 -Mutated Acute Myeloid Leukemia",

abstract = "Introduction: Mutated RUNX1 is considered a poor prognostic factor and usually is mutually exclusive with NPM1 mutations. Monitoring of molecular markers for minimal residual disease provides a powerful tool to assess remission and guide clinical decisions. Methods: Newly diagnosed RUNX1-mutated AML patients, designated to intensive chemotherapy-based treatment or nonintensive regimens, were monitored for mutated RUNX1 transcript levels by qPCR with patient-specific primers. Samples were obtained along the treatment course and follow-up. Results: A clear correlation was observed between mutated RUNX1 levels and response to treatment as observed by flow cytometry and STR-based assessment. Conclusion: We demonstrate the feasibility of RUNX1-based MRD to correlate with the clinicopathological status of leukemia. We further suggest how RUNX1 qPCR monitoring can influence clinical decision-making and contribute to improved personalized patient care.",

keywords = "Acute myeloid leukemia, Minimal residual disease, RUNX1 mutation",

author = "Boaz Nachmias and Svetlana Krichevsky and Dvora Filon and Ehud Even-Or and Gatt, \{Moshe E.\} and Revital Saban and Batia Avni and Sigal Grisariu and Shlomzion Aumann and Vladimir Vainstein",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.",

year = "2022",

month = nov,

day = "1",

doi = "10.1159/000526353",

language = "אנגלית",

volume = "145",

pages = "642--649",

journal = "Acta Haematologica",

issn = "0001-5792",

publisher = "S. Karger AG",

number = "6",

}

TY - JOUR

T1 - Monitoring Minimal Residual Disease in RUNX1 -Mutated Acute Myeloid Leukemia

AU - Nachmias, Boaz

AU - Krichevsky, Svetlana

AU - Filon, Dvora

AU - Even-Or, Ehud

AU - Gatt, Moshe E.

AU - Saban, Revital

AU - Avni, Batia

AU - Grisariu, Sigal

AU - Aumann, Shlomzion

AU - Vainstein, Vladimir

N1 - Publisher Copyright: © 2022 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.

PY - 2022/11/1

Y1 - 2022/11/1

N2 - Introduction: Mutated RUNX1 is considered a poor prognostic factor and usually is mutually exclusive with NPM1 mutations. Monitoring of molecular markers for minimal residual disease provides a powerful tool to assess remission and guide clinical decisions. Methods: Newly diagnosed RUNX1-mutated AML patients, designated to intensive chemotherapy-based treatment or nonintensive regimens, were monitored for mutated RUNX1 transcript levels by qPCR with patient-specific primers. Samples were obtained along the treatment course and follow-up. Results: A clear correlation was observed between mutated RUNX1 levels and response to treatment as observed by flow cytometry and STR-based assessment. Conclusion: We demonstrate the feasibility of RUNX1-based MRD to correlate with the clinicopathological status of leukemia. We further suggest how RUNX1 qPCR monitoring can influence clinical decision-making and contribute to improved personalized patient care.

AB - Introduction: Mutated RUNX1 is considered a poor prognostic factor and usually is mutually exclusive with NPM1 mutations. Monitoring of molecular markers for minimal residual disease provides a powerful tool to assess remission and guide clinical decisions. Methods: Newly diagnosed RUNX1-mutated AML patients, designated to intensive chemotherapy-based treatment or nonintensive regimens, were monitored for mutated RUNX1 transcript levels by qPCR with patient-specific primers. Samples were obtained along the treatment course and follow-up. Results: A clear correlation was observed between mutated RUNX1 levels and response to treatment as observed by flow cytometry and STR-based assessment. Conclusion: We demonstrate the feasibility of RUNX1-based MRD to correlate with the clinicopathological status of leukemia. We further suggest how RUNX1 qPCR monitoring can influence clinical decision-making and contribute to improved personalized patient care.

KW - Acute myeloid leukemia

KW - Minimal residual disease

KW - RUNX1 mutation

UR - https://www.scopus.com/pages/publications/85142939333

U2 - 10.1159/000526353

DO - 10.1159/000526353

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 35933982

AN - SCOPUS:85142939333

SN - 0001-5792

VL - 145

SP - 642

EP - 649

JO - Acta Haematologica

JF - Acta Haematologica

IS - 6

ER -

Monitoring Minimal Residual Disease in RUNX1 -Mutated Acute Myeloid Leukemia

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this